BioCentury
ARTICLE | Clinical News

Ark's ziresovir stops worsening of RSV symptoms in Phase II

November 16, 2018 4:05 PM UTC

Ark Biosciences Inc. (Shanghai, China) reported data from the Phase II VICTOR trial in hospitalized infants with respiratory syncytial virus (RSV) infection showing that no infant who received a single dose of oral ziresovir (AK0529) had worsening signs or symptoms of RSV disease over 24 hours. No serious adverse events were reported in the double-blind, placebo-controlled, international trial. The data were reported in an abstract ahead of the International Society for Influenza and other Respiratory Virus Diseases meeting in Washington...

BCIQ Target Profiles

RSV F protein